Early intravenous gamma-globulin treatment for Kawasaki disease: The nationwide surveys in Japan

Hiromi Muta, Masahiro Ishii, Kimiyasu Egami, Jun Furui, Yoko Sugahara, Teiji Akagi, Yoshikazu Nakamura, Hiroshi Yanagawa, Toyojiro Matsuishi


59 被引用数 (Scopus)


Objective: To determine the optimal period of intravenous gamma-globulin (IVGG) treatment, using the database from nationwide Kawasaki disease surveys in Japan. Study design: We selected patients who first visited a doctor within 3 days of illness and received IVGG treatment within 9 days of illness. We divided these patients into 2 groups: an early group (treated on days 1-4: 4731 cases) and a conventional group (days 5-9: 4020 cases). We compared the rate of additional IVGG and prevalence of cardiac sequelae between these groups. Results: The rate of additional IVGG in the early group was significantly higher than those of the conventional group (OR, 1.12 [95% CI, 1.10-1.16]). There were no significant differences in cardiac sequelae between the two groups. Conclusions: There is no evidence that IVGG treatment on day 4 or earlier has greater efficacy in preventing cardiac sequelae than treatment on days 5 to 9. In addition, early treatment is likely to result in a greater requirement for additional IVGG. However, there is also no evidence that early treatment increases the prevalence of cardiac sequelae in a clinical practice setting, where additional IVGG can be given to those whose initial treatment fails.

ジャーナルJournal of Pediatrics
出版ステータスPublished - 4月 2004

ASJC Scopus subject areas

  • 小児科学、周産期医学および子どもの健康


「Early intravenous gamma-globulin treatment for Kawasaki disease: The nationwide surveys in Japan」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。